Seppe Gevaert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seppe Gevaert has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Nancy Sferruzzi-Perri
University of Cambridge
1 shared publication Amitesh Panda
Department of Development and Regeneration, Leuven Stem Cell Institute, Leuven Institute for Single Cell Omics (LISCO), KU Leuven, Leuven, Belgium
1 shared publication- Andrei Segal
Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven; VIB Centre for Brain & Disease Research, Leuven, Belgium
1 shared publication - Anna Louise David
University College London
1 shared publication Evy Van Den Broeck
Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven; VIB Centre for Brain & Disease Research, Leuven, Belgium
1 shared publication- Jill Witvrouwen
Implantation, Placentation, Pregnancy & endometriosis (POPPYe) Research Group, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Placental TRPV2 supports trophoblast function and normal fetal development
While placental functioning arbitrates fetal outcome, the molecular players that underpin normal placental development remain poorly understood. Here, we provide evidence that the Transient Receptor Potential Vanilloid 2 (TRPV2) channel plays an important role in normal placental development, determining fetal size and survival. Its absence severely affects placental morphology, causing fetal growth restriction and embryonic lethality, which was found to be allocated to a non-redundant role in the trophoblast, but not in the embryo. CRISPR/Cas9-mediated Trpv2 deletion in mouse trophoblast stem cells demonstrated that Trpv2 contributes to the differentiation towards Syncytiotrophoblast layer II (SynTII) cells, which was confirmed by the growth restriction phenotype in SynTII-specific Trpv2 knockout animals. Finally, TRPV2 was functionally expressed in human trophoblast cells and enriched in trophoblast populations undergoing syncytial differentiation. Together, our findings identify an important role for TRPV2 during placental development and consequently fetal outcomes.
- 10 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessPlacental TRPV2 supports trophoblast function and normal fetal development
While placental functioning arbitrates fetal outcome, the molecular players that underpin normal placental development remain poorly understood. Here, we provide evidence that the Transient Receptor Potential Vanilloid 2 (TRPV2) channel plays an important role in normal placental development, determining fetal size and survival. Its absence severely affects placental morphology, causing fetal growth restriction and embryonic lethality, which was found to be allocated to a non-redundant role in the trophoblast, but not in the embryo. CRISPR/Cas9-mediated Trpv2 deletion in mouse trophoblast stem cells demonstrated that Trpv2 contributes to the differentiation towards Syncytiotrophoblast layer II (SynTII) cells, which was confirmed by the growth restriction phenotype in SynTII-specific Trpv2 knockout animals. Finally, TRPV2 was functionally expressed in human trophoblast cells and enriched in trophoblast populations undergoing syncytial differentiation. Together, our findings identify an important role for TRPV2 during placental development and consequently fetal outcomes.